|
Clinical trials are now underway to gain U.S. Food and Drug Administration (FDA) approval to bring hybrid technology to market.
Phase II of the Nucleus Hybrid clinical trial has recently closed to additional participants after enrolling nearly 100 individuals at 17 U.S. investigational sites.
The Med-El clinical trial of EAS, which plans to enroll approximately 55 participants at 15 study sites, has recently commenced in the United States. Clinical trail participants will be involved with the study for approximately 15 months.
For more information, contact:
|